zoledronic acid (zometa) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Zoledronic acid (Reclast, Aclasta, Zometa) is an intravenous, highly potent amino-bisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications vary between countries). Its high affinity to and long half-life in bone, and long duration of action allow for once-yearly administration, which has the potential to improve adherence to therapy. Zoledronic acid once yearly for up to 3 years improved bone mineral density (BMD) at several skeletal sites, reduced fracture risk and bone turnover, and/or preserved bone structure and mass relative to placebo in clinical studies in patients with primary or secondary osteoporosis. While additional benefits were seen when treatment was continued for up to 6 years, as evidenced by a reduced risk of vertebral fractures and higher BMD relative to 3 years’ therapy, there was the minimal advantage of treatment beyond 6 years. Therefore, in patients with low fracture risk, treatment discontinuation should be considered after approximately 5 years’ therapy. Zoledronic acid administered annually or once in 2 years was also effective in preventing bone loss in patients with low bone mass. Zoledronic acid was generally well tolerated, with the most common adverse events (AEs) being transient, mild-to-moderate post-infusion symptoms, which decreased with subsequent infusions.   NCATS

  • SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
  • InChIKey: XRASPMIURGNCCH-UHFFFAOYSA-N
  • Mol. Mass: 272.0896
  • ALogP: -1.12
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.2637 - $1066.4000

Australia

$56.4418 - $81.2514
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(1-hydroxy-2-(1h-imidazol-1-yl)ethylidene)bisphosphonic acid | (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid | 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid | aclasta | anhydrous zoledronic acid | cgp 42'446 | cgp-42446 | cgp-42'446 | cgp 42446a | novartis brand of zoledronic acid | reclast | zerlinda | zol | zoledronate | zoledronic acid | zoledronic acid anhydrous | zoledronic acid, anhydrous | zoledronic acid hydrate | zoledronic acid monohydrate | zoledronic acid / zoledronic acid monohydrate | zometa

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue